News

AxioMed Spine has received CE Mark approval for its Freedom lumbar disc, an elastomeric total spinal disc replacement device. The CE Mark approval was received from the notified

Canada-based Oncolytics Biotech has successfully completed patient enrollment in its multi-centre Phase II clinical trial to evaluate the intravenous administration of Reolysin in patients with various sarcomas that

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped enrollment into a clinical trial testing the effects of highly concentrated saline solutions

NovImmune, a Switzerland-based biotechnology company, has raised $54.8m to take back control of its lead compounds, NI-0401 and NI-0501, a fully human monoclonal antibody to CD3 and interferon-gamma,

Schering-Plough has initiated patient enrollment in RED-CABG, the Phase III trial for acadesine, an investigational adenosine regulating agent. Acadesine was licensed from PeriCor Therapeutics, a specialty biopharmaceutical company.

FY2009 Outlook AMDL reaffirms that it is on track with its FY2009 projections and expects to meet its FY2009 financial guidance of estimated gross revenues of $64 –

Cimzia can be dosed at 400 mg initially and at weeks two and four, followed by 200 mg every other week; for maintenance dosing, 400 mg every four

Financial Results Total revenue for the first nine months of fiscal 2009 was CAD4.8 million against CAD5.5 million for the first nine months of fiscal 2008. The majority

Osmetech has submitted a request to the FDA for emergency use authorization for its respiratory pathogen test panel test to be used to screen for the swine flu